Table of Contents: 1 Introduction 1.1 Definition 1.2 Scope of Study 1.3 Research Objective 1.4 Assumptions & Limitations 1.4.1 Assumptions 1.4.2 Limitations 1.5 Market Structure 2 Research Methodology 2.1 Research Process 2.2 Primary Research 2.3 Secondary Research 3 Market Dynamics 3.1 Drivers 3.1.1 Introduction 3.1.2 Development of New Drugs and Therapies 3.1.3 Financial Support from CFF in Research and Development of CF Drugs. 3.2 Restraints 3.2.1 Introduction 3.2.2 High Cost of the Drugs and Treatment 3.3 Opportunities 3.4 Challenges 3.4.1 Awareness About the Rare Disease in the Developing Countries 4 Market Factor Analysis 4.1 Porter’s Five Forces Model 4.1.1 Bargaining Power of Suppliers 4.1.2 Bargaining Power of Buyers 4.1.3 Threat of New Entrants 4.1.4 Threat of Substitutes 4.1.5 Intensity of Rivalry 5 Cystic Fibrosis Market, By Treatment Method 5.1 Introduction 5.2 Medication 5.3 Devices 5.4 Other Treatments 6 Cystic Fibrosis Market, By Regions 6.1 Introduction 6.2 North America 6.3 Europe 6.4 Asia-Pacific 6.5 Middle East & Africa 7 Company Share Analysis 8 Company Profile 8.1 AbbVie 8.1.1 Company Overview 8.1.2 Product Overview 8.1.3 Financials 8.1.4 Key Developments 8.2 Allergan Plc 8.2.1 Company Overview 8.2.2 Product Overview 8.2.3 Financials 8.2.4 Key Developments 8.3 Chiesi Farmaceutici S.p.A. 8.3.1 Company Overview 8.3.2 Product/Business Segment Overview 8.3.3 Financials 8.3.4 Key Developments 8.4 F. Hoffmann-La Roche AG 8.4.1 Company Overview 8.4.2 Product/Business Segment Overview 8.4.3 Financials 8.4.4 Key Developments 8.5 Gilead Sciences 8.5.1 Company Overview 8.5.2 Product Overview 8.5.3 Financials 8.5.4 Key Developments 8.6 Novartis AG 8.6.1 Company Overview 8.6.2 Product Overview 8.6.3 Financials 8.6.4 Key Developments   8.7 Pharmaxis Ltd. 8.7.1 Company Overview 8.7.2 Product Overview 8.7.3 Financials 8.7.4 Key Developments 8.8 PTC Therapeutics 8.8.1 Company Overview 8.8.2 Product Overview 8.8.3 Financials 8.8.4 Key Developments 8.9 Vertex Pharmaceuticals Incorporated 8.9.1 Company Overview 8.9.2 Product/Business Segment Overview 8.9.3 Financials

List of Tables: TABLE 1 GLOBAL CYSTIC FIBROSIS MARKET, BY TREATMENT METHOD, 2013-2022 ($MILLION) TABLE 2 GLOBAL CYSTIC FIBROSIS MEDICATION MARKET, BY REGION, 2013-2027 ($MILLION) TABLE 3 GLOBAL CYSTIC FIBROSIS DEVICES MARKET, BY REGION, 2013-2027 ($MILLION) TABLE 4 GLOBAL CYSTIC FIBROSIS OTHER TREATMENTS MARKET, BY REGION, 2013-2027 ($MILLION) TABLE 5 GLOBAL CYSTIC FIBROSIS MARKET, BY REGION, 2013-2022 ($MILLION) TABLE 6 NORTH AMERICA CYSTIC FIBROSIS MARKET, BY COUNTRY, 2013-2022 ($MILLION) TABLE 7 NORTH AMERICA CYSTIC FIBROSIS MARKET, BY TREATMENT METHOD, 2013-2022 ($MILLION) TABLE 8 U.S. CYSTIC FIBROSIS MARKET, BY TREATMENT METHOD, 2013-2022 ($MILLION) TABLE 9 CANADA CYSTIC FIBROSIS MARKET, BY TREATMENT METHOD, 2013-2022 ($MILLION) TABLE 10 EUROPE CYSTIC FIBROSIS MARKET, BY COUNTRY, 2013-2022 ($MILLION) TABLE 11 EUROPE CYSTIC FIBROSIS MARKET, BY TREATMENT METHOD, 2013-2022 ($MILLION) TABLE 12 GERMANY CYSTIC FIBROSIS MARKET, BY TREATMENT METHOD, 2013-2022 ($MILLION) TABLE 13 FRANCE CYSTIC FIBROSIS MARKET, BY TREATMENT METHOD, 2013-2022 ($MILLION) TABLE 14 U.K. CYSTIC FIBROSIS MARKET, BY TREATMENT METHOD, 2013-2022 ($MILLION) TABLE 15 ITALY CYSTIC FIBROSIS MARKET, BY TREATMENT METHOD, 2013-2022 ($MILLION) TABLE 16 SPAIN CYSTIC FIBROSIS MARKET, BY TREATMENT METHOD, 2013-2022 ($MILLION) TABLE 17 REST OF WESTERN EUROPE CYSTIC FIBROSIS MARKET, BY TREATMENT METHOD, 2013-2022 ($MILLION) TABLE 18 EASTERN EUROPE CYSTIC FIBROSIS MARKET, BY TREATMENT METHOD, 2013-2022 ($MILLION) TABLE 19 ASIA-PACIFIC CYSTIC FIBROSIS MARKET, BY COUNTRY, 2013-2022 ($MILLION) TABLE 20 ASIA-PACIFIC CYSTIC FIBROSIS MARKET, BY TREATMENT METHOD, 2013-2022 ($MILLION) TABLE 21 AUSTRALIA CYSTIC FIBROSIS MARKET, BY TREATMENT METHOD, 2013-2022 ($MILLION) TABLE 22 JAPAN CYSTIC FIBROSIS MARKET, BY TREATMENT METHOD, 2013-2022 ($MILLION) TABLE 23 CHINA CYSTIC FIBROSIS MARKET, BY TREATMENT METHOD, 2013-2022 ($MILLION) TABLE 24 INDIA CYSTIC FIBROSIS MARKET, BY TREATMENT METHOD, 2013-2022 ($MILLION) TABLE 25 REPUBLIC OF KOREA CYSTIC FIBROSIS MARKET, BY TREATMENT METHOD, 2013-2022 ($MILLION) TABLE 26 REST OF ASIA-PACIFIC CYSTIC FIBROSIS MARKET, BY TREATMENT METHOD, 2013-2022 ($MILLION) TABLE 27 MIDDLE EAST & AFRICA CYSTIC FIBROSIS MARKET, BY REGION, 2013-2022 ($MILLION) TABLE 28 MIDDLE EAST & AFRICA CYSTIC FIBROSIS MARKET, BY TREATMENT METHOD, 2013-2022 ($MILLION) TABLE 29 MIDDLE EAST CYSTIC FIBROSIS MARKET, BY TREATMENT METHOD, 2013-2022 ($MILLION) TABLE 30 AFRICA CYSTIC FIBROSIS MARKET, BY TREATMENT METHOD, 2013-2022 ($MILLION) TABLE 31 CHIESI FARMACEUTICI S.P.A.: KEY DEVELOPMENTS TABLE 32 VERTEX PHARMACEUTICALS INCORPORATED: KEY DEVELOPMENTS List of Figures: FIGURE 1 RESEARCH PROCESS OF MRFR FIGURE 2 PORTER'S 5 FORCES ANALYSIS OF GLOBAL CYSTIC FIBROSIS MARKET FIGURE 3 GLOBAL CYSTIC FIBROSIS MARKET, BY TREATMENT METHOD, 2015 & 2022 ($MILLION) FIGURE 4 GLOBAL CYSTIC FIBROSIS MARKET, BY REGION, 2015 (%) FIGURE 5 NORTH AMERICA CYSTIC FIBROSIS MARKET, BY COUNTRY, 2015 (%) FIGURE 6 NORTH AMERICA CYSTIC FIBROSIS MARKET, BY TREATMENT METHOD, 2015 & 2022 ($MILLION) FIGURE 7 EUROPE CYSTIC FIBROSIS MARKET, BY COUNTRY, 2015 (%) FIGURE 8 EUROPE CYSTIC FIBROSIS MARKET, BY TREATMENT METHOD, 2015 & 2022 ($MILLION) FIGURE 9 ASIA-PACIFIC CYSTIC FIBROSIS MARKET, BY COUNTRY, 2015 (%) FIGURE 10 ASIA-PACIFIC CYSTIC FIBROSIS MARKET, BY TREATMENT METHOD, 2015 % 2022 ($MILLION) FIGURE 11 MIDDLE EAST & AFRICA CYSTIC FIBROSIS MARKET, BY REGION, 2015 (%) FIGURE 12 MIDDLE EAST & AFRICA CYSTIC FIBROSIS MARKET, BY TREATMENT METHOD, 2015 & 2022 ($MILLION) FIGURE 13 CYSTIC FINROSIS MARKET SHARE, 2016 (%) FIGURE 14 ABBVIE: RECENT FINANCIAL FIGURE 15 ABBVIE: BUSINESS REVENUE, 2015 (%) FIGURE 16 ABBVIE: GEOGRAPHIC REVENUE, 2015 (%) FIGURE 17 ALLERGAN: RECENT FINANCIAL FIGURE 18 ALLERGAN: BUSINESS REVENUE, 2015 (%) FIGURE 19 ALLERGAN: GEOGRAPHIC REVENUE, 2015 (%) FIGURE 20 CHIESI FARMACEUTICI S.P.A.: RECENT FINANCIALS FIGURE 21 F. HOFFMANN-LA ROCHE AG.: RECENT FINANCIALS FIGURE 22 F. HOFFMANN-LA ROCHE AG.: BUSINESS REVENUE FIGURE 23 GILEAD SCIENCES: RECENT FINANCIAL FIGURE 24 NOVARTIS AG: RECENT FINANCIALS FIGURE 25 NOVARTIS AG: BUSINESS REVENUE, 2015 (%) FIGURE 26 NOVARTIS AG: GEOGRAPHIC REVENUE, 2015 (%) FIGURE 27 PHARMAXIS LTD: RECENT FINANCIALS FIGURE 28 PTC THERAPEUTICS: RECENT FINANCIALS FIGURE 29 PTC THERAPEUTICS: GEOGRAPHICAL REVENUE (%) FIGURE 30 PTC THERAPEUTICS: R&D EXPENSES, 2015 (%) FIGURE 31 VERTEX PHARMACEUTICALS INCORPORATED: RECENT FINANCIALS FIGURE 32 VERTEX PHARMACEUTICALS INCORPORATED: BUSINESS REVENUE FIGURE 33 VERTEX PHARMACEUTICALS INCORPORATED: GEOGRAPHICAL REVENUE

AbbVie, Allergan Plc, Chiesi Farmaceutici S.p.A., F. Hoffmann-La Roche AG, Gilead Sciences, Novartis AG, Pharmaxis Ltd., PTC Therapeutics, Vertex Pharmaceuticals Incorporated and others.